The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study.
J. Lefebvre
Consultant or Advisory Role - Merck Serono; Sanofi
Honoraria - Merck Serono; Sanofi
Y. Pointreau
No relevant relationships to disclose
F. Rolland
Honoraria - Merck Serono
M. Alfonsi
No relevant relationships to disclose
A. Baudoux
No relevant relationships to disclose
C. Sire
No relevant relationships to disclose
D. De Raucourt
No relevant relationships to disclose
E. Bardet
No relevant relationships to disclose
C. Tuchais
No relevant relationships to disclose
P. Garaud
No relevant relationships to disclose
G. Calais
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono